期刊
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
卷 18, 期 7, 页码 685-713出版社
WILEY
DOI: 10.1111/1756-185X.12754
关键词
drug treatment; rheumatoid arthritis
类别
资金
- AbbVie
- Janssen
- Pfizer
- Roche
- UCB
AimsRheumatoid arthritis is a chronic inflammatory condition that affects approximately 1% of the world's population. There are a wide number of guidelines and recommendations available to support the treatment of rheumatoid arthritis; however, the evidence used for these guidelines is predominantly based on studies in Caucasian subjects and may not be relevant for rheumatoid arthritis patients in the Asia-Pacific region. Therefore, the Asia Pacific League of Associations for Rheumatology established a Steering Committee in 2013 to address this issue. Materials and methodsThe AGREE II instrument and the ADAPTE Collaboration framework were applied to systematically identify, appraise, synthesize, and adapt international rheumatoid arthritis guidelines for use in the Asia-Pacific region. ResultsForty rheumatoid arthritis treatment recommendations, based on evidence and expert opinion, were drafted and are presented in this report. ConclusionThe Asia Pacific of Associations for Rheumatology rheumatoid arthritis treatment recommendations are intended to serve as a reference for best practice management of rheumatoid arthritis in Asia-Pacific, focusing on local issues to ensure the delivery of basic care for these patients, and to improve their outcomes. In addition, the document will serve as a reference for national rheumatology associations in Asia-Pacific for developing guidelines in their respective countries.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据